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Dermatologists are the primary treating physicians of skin cancer in the United States Medicare population
To the Editor: Surgical treatment of skin cancer has historically been performed by several different specialties. A study of 1998-1999 Medicare data showed that dermatologists performed nearly all destructions (95%) and Mohs micrographic surgeries (MMS; 100%) for nonmelanoma skin cancer (NMSC) but only a slight majority of excisions (56%). 1 Due to the large percentage of cases treated by dermatologists and their almost exclusive use of the least expensive setting (office), NMSC treatment accounted for \1% of cancer expenditures in the United States at that time. 1 However, surgical specialties were found to have significantly higher mean NMSC treatment costs ($957) compared with dermatology ($604) because surgical specialties primarily performed excisions (not destructions) and routinely used operating rooms and ambulatory surgical centers. 1 Thus, there remains concern regarding skin cancer treatment costs, particularly as skin cancer incidence continues to rise. This study aims to provide an update on the roles played by dermatologists and other specialists in skin cancer treatment.
The most recent publicly available Medicare provider level claims data (2012-2015) were used to identify the number of procedures performed by each physician for skin cancer treatment-related current procedural terminology (CPT) codes: 1) malignant excisions (11600-11646); 2) malignant destructions (17260-17286); and 3) first-stage MMS (17311, 17313). Physicians were categorized by specialty and geographic region. The number of procedures performed annually (averaged over 2012-2015) was calculated for each specialty and stratified by region.
During 2012-2015, a total of 8330 physicians performed skin cancer treatment procedures in the Medicare population. Most were dermatologists (84.0%), followed by plastic surgeons (6.4%), general surgeons (2.4%), otolaryngologists (2.1%), family physicians (1.1%), and other specialists (2.0%). Dermatologists performed nearly all destructions (97.1%), MMSs (98.1%), and a large majority of excisions (85.4%) (Table I) , overall accounting for 95% of procedures, which was consistent across geographic regions (Fig 1) . The next leading specialty, plastic surgery, performed 2.5% of procedures.
This study demonstrated a large increase in the percentage of excisions performed by dermatologists, from 56% during 1998-1999 to 85% during 2012-2015, and a consistently high percentage of destructions and MMSs performed by dermatologists for skin cancer. The total number of skin cancer treatment procedures performed annually increased by [50% during 2000-2015, due in part to rising skin cancer incidence. 2 Dermatologists treated most of these additional cases and subsequently assumed the role of the primary physician treating skin cancer.
There are likely to be errors in the data set used, which relies on providers and billing personnel correctly reporting CPT codes and specialty. However, it is improbable that errors would be systematic and substantially affect the overall findings.
In the present study, dermatologists performed 95% of all skin cancer treatment procedures, up from 82% in 1998-1999. Possible explanations for this change include increased demand for dermatologists due to the more economical office-based setting they use for treatment 1 and recent findings demonstrating that primary care physicians preferentially refer to and patients seek dermatologists for treatment due to perceived expertise in skin cancer surgery. 3, 4 Meanwhile, the supply of dermatologists comfortable with performing surgical treatment of skin cancer has increased as surgical training has become an integral part of the curriculum in dermatology residencies and as the number of Mohs surgeons who exclusively specialize in skin cancer surgery has grown. BCC, Basal cell carcinoma; IL, interleukin; SD, standard deviation; T0, baseline time point; T1, time point after incubation with photosensitizer; T2, time point after irradiation; TNF, tumor necrosis factor. *Limits of detection of cytokines were 7.2 pg/mL for IL-1, 2.5 pg/mL for IL-6, 3.6 pg/mL for IL-8, 3.3 pg/mL for IL-10, 1.9 pg/mL for IL-12p70, and 3.7 pg/mL for TNF.
